MA30503B1 - Polypeptides du facteur de croissance de type insuline stabilises. - Google Patents

Polypeptides du facteur de croissance de type insuline stabilises.

Info

Publication number
MA30503B1
MA30503B1 MA31459A MA31459A MA30503B1 MA 30503 B1 MA30503 B1 MA 30503B1 MA 31459 A MA31459 A MA 31459A MA 31459 A MA31459 A MA 31459A MA 30503 B1 MA30503 B1 MA 30503B1
Authority
MA
Morocco
Prior art keywords
polypeptides
growth factor
type growth
insulin type
stabilized insulin
Prior art date
Application number
MA31459A
Other languages
English (en)
Inventor
David Jonathan Glass
Mara Fornaro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38801859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30503(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30503B1 publication Critical patent/MA30503B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

L'invention concerne des polypeptides stabilisés ayant une séquence IGF-1 ou IGF-2 et une séquence de peptide E, où le clivage physiologique naturel du peptide E à partir de IGF est prévenu.
MA31459A 2006-06-09 2008-12-08 Polypeptides du facteur de croissance de type insuline stabilises. MA30503B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81234906P 2006-06-09 2006-06-09
US86224406P 2006-10-20 2006-10-20
US89718707P 2007-01-24 2007-01-24

Publications (1)

Publication Number Publication Date
MA30503B1 true MA30503B1 (fr) 2009-06-01

Family

ID=38801859

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31459A MA30503B1 (fr) 2006-06-09 2008-12-08 Polypeptides du facteur de croissance de type insuline stabilises.

Country Status (32)

Country Link
US (4) US8343918B2 (fr)
EP (2) EP2032155B1 (fr)
JP (2) JP2009539805A (fr)
KR (1) KR101459789B1 (fr)
AR (1) AR061242A1 (fr)
AU (2) AU2007257936B2 (fr)
BR (2) BRPI0712147A2 (fr)
CA (2) CA2654944C (fr)
CL (1) CL2007001614A1 (fr)
CR (2) CR10432A (fr)
CY (1) CY1116117T1 (fr)
DK (2) DK2032155T3 (fr)
EC (1) ECSP088949A (fr)
ES (1) ES2529261T3 (fr)
GT (1) GT200800273A (fr)
HR (1) HRP20150326T1 (fr)
IL (1) IL195156A (fr)
JO (1) JO2968B1 (fr)
MA (1) MA30503B1 (fr)
MX (2) MX2008015726A (fr)
MY (1) MY147856A (fr)
NO (2) NO20085184L (fr)
NZ (2) NZ572548A (fr)
PE (1) PE20080715A1 (fr)
PL (1) PL2032155T3 (fr)
PT (1) PT2032155E (fr)
RU (1) RU2477287C2 (fr)
SI (1) SI2032155T1 (fr)
TN (1) TNSN08509A1 (fr)
TW (1) TWI427084B (fr)
UA (1) UA97953C2 (fr)
WO (2) WO2007141309A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090318355A1 (en) * 2006-02-15 2009-12-24 Chen Thomas T Compositions and methods for promoting tissue repair and wound healing
US8343918B2 (en) * 2006-06-09 2013-01-01 Novartis Ag Stabilized insulin-like growth factor polypeptides
ES2629853T3 (es) 2008-05-07 2017-08-16 Biomarin Pharmaceutical Inc. Péptidos de dirección lisosómica y usos de los mismos
EP2356148A2 (fr) * 2008-11-10 2011-08-17 Novartis AG Anticorps anti-peptides igf-1/e humain modifié
WO2010088502A2 (fr) * 2009-01-30 2010-08-05 The Regents Of The University Of California Signalisation du facteur de croissance analogue à l'insuline et intégrine
CA2993053A1 (fr) 2009-04-27 2010-11-04 Novartis Ag Anticorps anti-recepteur de l'activine iib (actriib) destines a augmenter la croissance musculaire
US8759299B2 (en) * 2009-07-22 2014-06-24 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (IGF-1) having amino acid substitution at position 59
US20120321595A1 (en) 2009-11-09 2012-12-20 The Brigham And Women's Hospital, Inc. Treatment of heart disease
JP2011160696A (ja) * 2010-02-08 2011-08-25 Novartis Ag 修飾ヒトｉｇｆ−１／ｅペプチドに対する抗体
AU2012220558A1 (en) 2011-02-23 2013-08-22 Massachusetts Institute Of Technology Water soluble membrane proteins and methods for the preparation and use thereof
WO2012178146A1 (fr) * 2011-06-24 2012-12-27 Isis Pharmaceuticals, Inc. Compositions et méthodes de traitement de la maladie d'aran-duchenne
DK2726099T3 (en) 2011-07-01 2018-11-05 Novartis Ag Method of treating metabolic disorders
WO2014012025A2 (fr) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Protéines igf-1 et leurs utilisations thérapeutiques
EP3626735A1 (fr) * 2012-12-18 2020-03-25 Novartis AG Polypeptides stabilisés de facteur de croissance de type insuline
CN104884467A (zh) 2012-12-18 2015-09-02 诺华股份有限公司 在遗传修饰的哺乳动物细胞中生产治疗性蛋白质
CA2918300A1 (fr) 2013-08-14 2015-02-19 Novartis Ag Procede de traitement de la myosite a corps d'inclusion sporadique
BR112016005716A2 (pt) * 2013-10-02 2017-09-12 Nat Institutes Of Health miméticos de fator de crescimento semelhante à insulina para uso em terapia
UY35874A (es) * 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
ES2872998T3 (es) 2013-12-19 2021-11-03 Puretein Bioscience Llc Procedimientos de tratamiento de animales
JP2017510622A (ja) 2014-01-27 2017-04-13 ノバルティス アーゲー 筋萎縮を予測するバイオマーカー、方法および使用
WO2015149085A2 (fr) * 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Protéines membranaires hydrosolubles et leurs procédés de préparation et d'utilisation
US10373702B2 (en) 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
EP3253405A4 (fr) * 2015-02-04 2018-07-04 Puretein Bioscience, LLC Procédés pour augmenter les caractéristiques de performance dans un descendant
KR101669140B1 (ko) * 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
CA3000742A1 (fr) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Proteines therapeutiques bispecifiques pour la reparation de tissus
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
SI3600415T1 (sl) 2017-03-24 2026-01-30 Novartis Ag Protitelo proti aktivinskemu receptorju tipa ii za uporabo pri zdravljenju srčnega popuščanja
JP6691503B2 (ja) * 2017-04-13 2020-04-28 任天堂株式会社 ゲームプログラム、ゲーム処理制御方法、およびゲーム装置
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
TW202342509A (zh) * 2022-01-31 2023-11-01 國立大學法人信州大學 以IGF1R為標的之pre-pro前驅體型嵌合抗原受體表現細胞
CN119569848A (zh) * 2024-11-22 2025-03-07 福建省农业科学院畜牧兽医研究所 一种鸭源igf2重组蛋白及其制备方法与应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
ATE81779T1 (de) 1985-08-22 1992-11-15 Gropep Pty Ltd Peptidanalogedes insulinaehnlichen wachstumsfaktors-1 bei saeugetieren.
JP2507106B2 (ja) 1987-12-24 1996-06-12 グロペップ プロプライエタリー リミテッド インスリン様成長因子１（ｉｇｆ―１）または因子２（ｉｇｆ―２）の類縁ペプチド
GB8819826D0 (en) * 1988-08-20 1988-09-21 Kabivitrum Ab Glycosylated igf-1
AU4238493A (en) * 1992-05-08 1993-12-13 Thomas Jefferson University IGF-1 analogs
WO1995013290A1 (fr) 1993-11-12 1995-05-18 North Shore University Hospital Research Corporation Methode pour traiter la dystrophie musculaire
WO1995032003A1 (fr) 1994-05-24 1995-11-30 Amgen Boulder Inc. Facteurs de croissance proches de l'insuline modifies
GB9605124D0 (en) * 1996-03-11 1996-05-08 Royal Free Hosp School Med Method of treating muscular disorders
US7118752B2 (en) 1998-07-22 2006-10-10 University Of Connecticut Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I
CA2356109C (fr) * 1999-01-06 2008-04-22 Genentech, Inc. Variants mutants du facteur de croissance insulinomimetique (igf) de type i
GB9926968D0 (en) * 1999-11-15 2000-01-12 Univ London Treatment of neurological disorders
GB0011278D0 (en) 2000-05-10 2000-06-28 Univ London Repair of nerve damage
IL158418A0 (en) * 2001-04-19 2004-05-12 Scripps Research Inst In vivo incorporation of unnatural amino acids
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
EP1576137A4 (fr) 2002-10-29 2010-06-30 Genentech Inc Compositions et methodes de traitement de maladies liees au systeme immunitaire
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
GB0426154D0 (en) 2004-11-29 2004-12-29 European Molecular Biology Lab Embl IGF-1 novel peptides
EP1674113A1 (fr) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugués de l'IGF-1 et du poly(éthylène glycol)
AU2006203882B2 (en) * 2005-01-07 2011-05-12 Regeneron Pharmaceuticals, Inc. IGF-1 fusion polypeptides and therapeutic uses thereof
JP2008533114A (ja) * 2005-03-18 2008-08-21 ユーシーエル ビジネス パブリック リミテッド カンパニー メカノ成長因子ペプチドおよびその使用
EP1868637A1 (fr) 2005-03-18 2007-12-26 UCL Business PLC Peptides de facteur de croissance mécano et leur utilisation
US20090271875A1 (en) 2005-03-31 2009-10-29 Pioneer Corporation Upgrade Module, Application Program, Server, and Upgrade Module Distribution System
US8343918B2 (en) 2006-06-09 2013-01-01 Novartis Ag Stabilized insulin-like growth factor polypeptides

Also Published As

Publication number Publication date
AU2007257936B2 (en) 2011-05-26
CL2007001614A1 (es) 2008-08-08
US8722621B2 (en) 2014-05-13
MX2008015657A (es) 2009-02-04
US20170066808A9 (en) 2017-03-09
CA2653781A1 (fr) 2007-12-13
ECSP088949A (es) 2009-01-30
NZ572548A (en) 2011-06-30
WO2007141309A3 (fr) 2008-05-29
JP5290966B2 (ja) 2013-09-18
CA2654944A1 (fr) 2007-12-21
IL195156A0 (en) 2011-08-01
RU2008151511A (ru) 2010-07-20
NZ572708A (en) 2011-11-25
TWI427084B (zh) 2014-02-21
DK2032155T3 (en) 2015-03-02
BRPI0712147A2 (pt) 2012-02-22
ES2529261T3 (es) 2015-02-18
BRPI0712052A2 (pt) 2012-01-10
PT2032155E (pt) 2015-04-07
JP2009539805A (ja) 2009-11-19
AU2007255419A1 (en) 2007-12-13
CA2654944C (fr) 2017-01-03
KR101459789B1 (ko) 2014-11-07
EP2032154A2 (fr) 2009-03-11
AR061242A1 (es) 2008-08-13
JO2968B1 (en) 2016-03-15
KR20090027197A (ko) 2009-03-16
CR10432A (es) 2009-01-15
PE20080715A1 (es) 2008-07-25
RU2477287C2 (ru) 2013-03-10
EP2032155B1 (fr) 2014-12-24
EP2032155A2 (fr) 2009-03-11
MY147856A (en) 2013-01-31
US20140235538A1 (en) 2014-08-21
NO20085184L (no) 2009-03-03
US20130059779A1 (en) 2013-03-07
CY1116117T1 (el) 2017-02-08
US20100234290A1 (en) 2010-09-16
CR20160115A (es) 2016-06-14
WO2007146689A3 (fr) 2008-04-10
WO2007146689A9 (fr) 2010-12-16
US8343918B2 (en) 2013-01-01
IL195156A (en) 2014-07-31
PL2032155T3 (pl) 2015-05-29
UA97953C2 (uk) 2012-04-10
TW200835698A (en) 2008-09-01
WO2007146689A2 (fr) 2007-12-21
US20100173839A1 (en) 2010-07-08
JP2009539383A (ja) 2009-11-19
NO20085183L (no) 2009-03-09
WO2007141309A2 (fr) 2007-12-13
TNSN08509A1 (en) 2010-04-14
HK1126429A1 (en) 2009-09-04
MX2008015726A (es) 2008-12-19
GT200800273A (es) 2009-09-16
DK200900016A (da) 2009-01-06
HRP20150326T1 (hr) 2015-04-24
AU2007257936A1 (en) 2007-12-21
SI2032155T1 (sl) 2015-04-30

Similar Documents

Publication Publication Date Title
JO2968B1 (en) Polypeptides are a stable insulin-like growth factor
BRPI0606612A2 (pt) expressão recombinante de proteìnas em uma forma de duas cadeias ligadas por dissulfeto
PL1891105T3 (pl) Analogi oksyntomoduliny i ich wpływ na zachowania żywieniowe
IN2014CN02050A (fr)
Darie et al. Mass spectrometric evidence that proteolytic processing of rainbow trout egg vitelline envelope proteins takes place on the egg
EP1548107A4 (fr) Chromoproteine et fluoroproteines
ATE447612T1 (de) Fluoreszenzproteine
AU2002345804A1 (en) Antimicrobially active peptide
DE602006016133D1 (de) Verwendung von stefin a als gerüstprotein
CY1111630T1 (el) Παραγωγα κυτοκινων
DE60029748D1 (de) Biologische bekämpfung von nematoden
WO2005123760A3 (fr) Traitement du cancer
EP1557466A4 (fr) Proteine d'antigene tumoral et utilisation de cette derniere
WO2006093824A3 (fr) Dispositif de collecte de virus de la grippe
GT200400123AA (es) Modulacion de los niveles de un precursor de saborizante de cafe en los granos de cafe verde (solicitud fraccionaria)
Asfar et al. Angiotensin-II: More Than Just Another Vasoconstrictor to Treat Septic Shock–Induced Hypotension?
Huybrechts et al. Osmotic lysis of corpora cardiaca using distilled water reveals the presence of partially processed peptides and peptide fragments
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
DE602007009292D1 (de) Neue ketolasen zur herstellung von ketocarotenoiden in targets
ES2260624T3 (es) Deteccion de mutaciones.
ATE459650T1 (de) KOMPLEMENTÄRE PEPTIDE FÜR ß-AMYLOID 29-42-PEPTID
DE602004020771D1 (de) Recombinante igf expressionssysteme
Grant Making proteins work(I)
WO2004005322A3 (fr) Proteine verte fluorescente renilla reniformis humanisee utilisee comme proteine d'echafaudage
Zhang Molecular cloning of cDNAs coding for four classes of lepidopteran aminopeptidases N from the midgut of Trichoplusia ni